(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Nature's Best: A Manual for Beautiful Train Rides - 2Extraordinary Picks for Home Apparatuses: Making Life Simpler
- 36 Objections for an Ocean side Wedding
- 4Civil rights leader Jesse Jackson hospitalized, family requests prayers
- 5Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- Middle East hotels hit pandemic-era lows amid Iran war
- The Following Huge Thing: 5 Progressive Tech New businesses
- Instructions to Pick the Right Dental Embed Trained professional: An Exhaustive Aide
- People Are Sharing The One Picture They Can't See Without Laughing, And It's The Comedy Spiral You Need Today
- Divorce filings, feuds and legal trouble: The 'Mormon Wives' drama keeps piling up
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- One of the best meteor showers of the year peaks at the worst possible time this week
- The hunt for dark matter: a trivia quiz
- How do my eyes adjust to the dark and how long does it take?
